WO2000061175A3 - Use of pegylated interferon alpha in melanoma therapy - Google Patents

Use of pegylated interferon alpha in melanoma therapy Download PDF

Info

Publication number
WO2000061175A3
WO2000061175A3 PCT/US2000/009129 US0009129W WO0061175A3 WO 2000061175 A3 WO2000061175 A3 WO 2000061175A3 US 0009129 W US0009129 W US 0009129W WO 0061175 A3 WO0061175 A3 WO 0061175A3
Authority
WO
WIPO (PCT)
Prior art keywords
pegylated interferon
interferon alpha
melanoma therapy
melanoma
alfa
Prior art date
Application number
PCT/US2000/009129
Other languages
French (fr)
Other versions
WO2000061175A2 (en
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU42046/00A priority Critical patent/AU771569B2/en
Priority to BR0009646-6A priority patent/BR0009646A/en
Priority to HU0200775A priority patent/HU230057B1/en
Priority to DK05002951T priority patent/DK1535622T3/en
Publication of WO2000061175A2 publication Critical patent/WO2000061175A2/en
Publication of WO2000061175A3 publication Critical patent/WO2000061175A3/en
Priority to NO20014852A priority patent/NO328111B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., preferably pegylated interferon alfa-2b, as adjuvant therapy to definitive surgery are disclosed.
PCT/US2000/009129 1999-04-08 2000-04-06 Use of pegylated interferon alpha in melanoma therapy WO2000061175A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU42046/00A AU771569B2 (en) 1999-04-08 2000-04-06 Melanoma therapy
BR0009646-6A BR0009646A (en) 1999-04-08 2000-04-06 Melanoma therapy
HU0200775A HU230057B1 (en) 1999-04-08 2000-04-06 Melanoma therapy
DK05002951T DK1535622T3 (en) 1999-04-08 2000-04-06 Melanoma therapy
NO20014852A NO328111B1 (en) 1999-04-08 2001-10-05 Use of a pegylated interferon alfa-2b for the manufacture of a medicament for the treatment of a patient having a surgically removed melanoma.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08
US09/288,366 1999-04-08

Publications (2)

Publication Number Publication Date
WO2000061175A2 WO2000061175A2 (en) 2000-10-19
WO2000061175A3 true WO2000061175A3 (en) 2001-02-01

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009129 WO2000061175A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha in melanoma therapy

Country Status (22)

Country Link
EP (3) EP2025344B1 (en)
JP (1) JP2000319195A (en)
CN (1) CN1390132A (en)
AR (1) AR023398A1 (en)
AT (3) ATE296639T1 (en)
AU (1) AU771569B2 (en)
BR (1) BR0009646A (en)
CA (1) CA2303992A1 (en)
CO (1) CO5170404A1 (en)
CY (1) CY1108922T1 (en)
DE (3) DE60045591D1 (en)
DK (2) DK1043026T3 (en)
ES (2) ES2319776T3 (en)
HK (2) HK1032349A1 (en)
HU (1) HU230057B1 (en)
MY (1) MY126763A (en)
NO (1) NO328111B1 (en)
PE (1) PE20010027A1 (en)
PT (2) PT1043026E (en)
TW (1) TWI292320B (en)
WO (1) WO2000061175A2 (en)
ZA (1) ZA200108173B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476943A (en) * 2011-03-10 2013-12-25 普罗维克图斯药品公司 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (en) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0730470B1 (en) 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (en) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUKOWSKI RONAL ET AL: "Phase I Study of Polyethylene Glycol ( PEG ) Interferon Alpha -2B ( PEG INTRON ) in Patients with Solid Tumors (Meeting abstract).", PROC ANNU MEET AM SOC CLIN ONCOL, vol. 18, May 1999 (1999-05-01), pages A1719, XP000953163 *
KIRKWOOD JOHN M ET AL: "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial EST 1684.", JOURNAL OF CLINICAL ONCOLOGY, vol. 14, no. 1, 1996, pages 7 - 17, XP000953174, ISSN: 0732-183X *
TALPAZ M ET AL: "Phase I study of pegylated-interferon alpha-2a (PEGASYSTM) in patients with chronic myelogenous leukemia (CML).", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), pages 530a, XP000953172, ISSN: 0006-4971 *
TALPAZ M ET AL: "Phase I study of polyethylene glycol (PEG) interferon alpha-2B (Intron-A) in CML patients.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), pages 251A, XP000953118, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
ATE296639T1 (en) 2005-06-15
TWI292320B (en) 2008-01-11
ES2239954T3 (en) 2005-10-16
PE20010027A1 (en) 2001-02-05
WO2000061175A2 (en) 2000-10-19
AR023398A1 (en) 2002-09-04
JP2000319195A (en) 2000-11-21
EP1043026A3 (en) 2000-12-20
MY126763A (en) 2006-10-31
EP2025344A1 (en) 2009-02-18
CY1108922T1 (en) 2014-07-02
HUP0200775A2 (en) 2002-08-28
DE60020444T2 (en) 2006-05-04
DE60045591D1 (en) 2011-03-10
ZA200108173B (en) 2003-01-06
CN1390132A (en) 2003-01-08
ATE496631T1 (en) 2011-02-15
HK1032349A1 (en) 2001-07-20
AU4204600A (en) 2000-11-14
ATE419001T1 (en) 2009-01-15
NO20014852L (en) 2001-12-06
NO328111B1 (en) 2009-12-07
EP2025344B1 (en) 2011-01-26
EP1535622A1 (en) 2005-06-01
HU230057B1 (en) 2015-06-29
CA2303992A1 (en) 2000-10-08
EP1043026B1 (en) 2005-06-01
HK1075416A1 (en) 2005-12-16
PT1043026E (en) 2005-09-30
CO5170404A1 (en) 2002-06-27
EP1535622B1 (en) 2008-12-31
DK1535622T3 (en) 2009-04-20
NO20014852D0 (en) 2001-10-05
DE60041290D1 (en) 2009-02-12
EP1043026A2 (en) 2000-10-11
AU771569B2 (en) 2004-03-25
PT1535622E (en) 2009-03-19
HUP0200775A3 (en) 2002-09-30
ES2319776T3 (en) 2009-05-12
BR0009646A (en) 2002-02-05
DK1043026T3 (en) 2005-07-04
DE60020444D1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
AU2002341558A1 (en) Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
DK1827500T3 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
WO1999004772A3 (en) Use of levobupivacaine
AU3247593A (en) Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
EP1440690A3 (en) Treatment of neurotic disorders
PL342099A1 (en) Therapeutic agents
HUP0003546A3 (en) Compositions for administering taxanes orally to human patients
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
SE9902597D0 (en) New use
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
ZA967915B (en) Therapeutic administration of hemoglobin in cardiac arrest
WO2000061174A3 (en) Use of pegylated interferon alpha for renal cell carcinoma treatment
WO2000061175A3 (en) Use of pegylated interferon alpha in melanoma therapy
IL131478A0 (en) Methods for treatment of scar tissue
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2000051631A3 (en) Pegylated alpha interferon for hiv therapy
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
EP1221945A4 (en) Methods, pharmaceutical and therapeutic compositions for administering adenosine
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808452.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 514416

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/08173

Country of ref document: ZA

Ref document number: 200108173

Country of ref document: ZA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP